Benefits in doubt as 50% of new drugs fail to impress in Germany
This article was originally published in SRA
Many pharmaceutical companies are having a hard time demonstrating to Germany's health technology assessment authorities that their medicinal products offer sizeable additional benefits, according to research by Scrip Regulatory Affairs' sister publication Scrip Intelligence. The table below shows which medicines have come out on top and which have struggled.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.